Altair Nanotechnologies Invited to Present At the 47th Institutional Investor Conference in New York.Business Editors & High-Tech Writers RENO, Nev.--(BUSINESS WIRE)--Feb. 5, 2003 Dr. Rudi E. Moerck to Present Altair's Drug Delivery Technology Platform and New Nano-Based Pharmaceutical, RenaZorb(TM), to the Analysts and Portfolio Managers Attending the Conference's Drugs and Biotechnology Industry Sector Presentations Altair Nanotechnologies Inc. (Nasdaq:ALTI) today announced that its President Dr. Rudi E. Moerck has been invited to present at the 47th Institutional Investor Institutional Investor A non-bank person or organization that trades securities in large enough share quantities or dollar amounts that they qualify for preferential treatment and lower commissions. Conference organized by The Wall Street Analyst Forum. The conference is being held at the Roosevelt Hotel
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Feb. 10 through Feb. 13, 2003. Moerck will present Tuesday, Feb. 11 at 8:20 a.m. and at 12:30 p.m. Both presentations will be followed by a 10-minute question and answer session and a separate room will be available for the investment community to meet with Moerck and Altair's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Dr. William P. Long following the question and answer session. Approximately 100 public companies will be presenting at the conference. Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at 802/253-7596. In addition to discussing Altair's technology for RenaZorb, the company's new drug for phosphate control in kidney dialysis Dialysis, Kidney Definition Dialysis treatment replaces the function of the kidneys, which normally serve as the body's natural filtration system. patients, Moerck will also talk about Altair's nano-based drug delivery system for pharmaceuticals in general. The Altair drug delivery platform has the potential to reduce side effects Side effects Effects of a proposed project on other parts of the firm. and to improve efficacy of existing drugs. The Wall Street Analyst Forum Inc. is the largest non-brokerage sponsor of analyst conferences in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . Each of their four annual New York industry-specific conferences brings together the CEOs and CFOs of public corporations with approximately 800 buy- and sell-side analysts and portfolio managers and thousands of additional investors who listen via live or delayed webcast. Bloomberg, First Call, E*TRADE, Zacks and other financial portals all promote webcast attendance of the corporate presentations. Investors may access an Internet webcast of the presentation at: http://events.onlinebroadcasting.com/fdfn/wsaf/021003/index.php or by visiting Altair's Web site, www.altairnano.com. Simply click on the Corporate Information link at the top of the page and then click on the audio presentation link titled "Dr. Rudi E. Moerck at the Wall Street Analyst Forum Conference ... " Altair Nanotechnologies Inc. Nanotechnology is rapidly emerging as a unique industry sector. Altair Nanotechnologies is positioning itself through product innovation within this emerging industry to become a leading supplier of nanomaterials and technology worldwide. Altair owns a proprietary technology for making nanocrystalline materials of unique quality both economically and in large quantities. The company is currently developing special nanomaterials with potential applications in pharmaceuticals, advanced energy storage devices, thermal spray Thermal Spray techniques are coating processes which involve spraying melted (or heated) materials onto a surface. As such thermal spraying is a line-of-sight process. The energy to heat the feedstock (coating precursor) is supplied by electrical (plasma or arc) or chemical means coatings, fuel cells, solar cells, catalysts, cosmetics, paints and environmental remediation. For additional information on Altair's nanoparticle materials, visit www.altairnano.com. Forward-Looking Statements This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, may involve risks, uncertainties and other factors that may cause the company's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, biological testing of the pharmaceuticals may not be successful, the pharmaceuticals may not obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval and Altair, without the assistance of a strategic partner, may not be capable of funding the FDA approval cycle. Additionally, the company may be unable to attract additional customers, fund additional research or product development through its sales and branding campaign. The company may never earn sufficient revenues to be profitable; its nanoparticle products may not be integrated into any major market groups and products. In addition, other risks are identified in the company's most recent Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , as filed with the SEC. Such forward-looking statements speak only as of the date of this release. The company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion